ArticleStatistics in medicine2026
Simultaneous Representation Learning of Multi-Omics and Clinical Outcome Data via a Supervised Knowledge-Guided Bayesian Factor Model.
Article in Statistics in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
With the advent of high-throughput techniques, multi-omics data and various clinical outcomes have been collected for a range of diseases. Multi-omics data play a crucial role in uncovering complex biological processes, yet simultaneous representation learning of such high-dimensional, heterogeneous multi-modality data along with clinical outcomes remains limited. To address this gap, we propose a supervised knowledge-guided Bayesian factor model for integrative analysis of multi-omics and clinical outcome data. The proposed method simultaneously extracts an informative low-dimensional representation and predicts one or more clinical outcomes of interest. The two-level adaptive shrinkage in the novel hierarchical priors allows for the identification of both active modalities and features, resulting in a biologically meaningful structural identification of the high-dimensional data. Moreover, the method is robust to noisy edges in biological graphs that do not align with ground truth. Finally, the proposed method can handle different data types including both continuous and categorical data. Extensive simulation studies and real data analyses of Alzheimer's disease (AD) data demonstrate the advantages of the proposed approach over existing methods. Notably, our analysis of multi-omics and imaging phenotype data from ADNI provides meaningful insights into the underlying biological mechanisms of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.